Details Basic Details Approval Date Wednesday, February 15, 2017 Health Outcome(s) adverse pregnancy and fetal outcomes, fatal major adverse cardiac events, hospitalized neutropenia, malignancy, myocardial infarction and stroke, opportunistic infections, outpatient neutropenia, serious infection, suicidal ideation and behavior Regulatory Link(s) (2) ARIA Memo FDA Approval Package Link(s) Sentinel Drug Study: Siliq (Brodalumab) & Hospitalized Neutropenia, Myocardial Infarction and Stroke, and Serious Infection